You are here: Industry Insights > SARS-CoV-2

News List

Study finds Covid-19 coronavirus of natural origin pharmaceutical-technology
March 20, 2020
A new study led by Scripps Research Institute has shown that the novel coronavirus, SARS-CoV-2, which causes Covid-19, is of natural origin and not engineered in a laboratory.
The COVID-19 coronavirus epidemic has a natural origin worldpharmanews
March 19, 2020
The novel SARS-CoV-2 coronavirus that emerged in the city of Wuhan, China, last year and has since caused a large scale COVID-19 epidemic ...
Diatherix Eurofins Launches SARS-CoV-2 Virus Identification Test contractpharma
March 19, 2020
New COVID-19 Panel tests for the SARS-CoV-2 virus along with five bacterial pathogens.
Quick Look at the Anti-epidemic Monoclonal Antibodies that Target the Novel Coronavirus S Protein PharmaSources/Xiaoyaowan
March 17, 2020
The General Office of the National Health Commission and the Office of the National Administration of Traditional Chinese Medicine of China issued the COVID-19 Diagnosis and Treatment Scheme (Trial Version 6) on Feb. 19. It's worth noting that the scheme
Deuterium Depletion as a Possible New Strategy to Combat SARS-CoV-2 prnasia
March 16, 2020
Since December 2019, the world is facing the new coronavirus challenge, and measures have been taken against the outbreak.
Roche’s SARS-CoV-2 Test Receives EUA contractpharma
March 16, 2020
First commercial test for SARS-CoV-2 will enable expedited coronavirus testing with results in three and half hours.
Luminex Provides Update on SARS-CoV-2 Validation Testing Efforts americanpharmaceuticalreview
March 16, 2020
Luminex announced that four independent clinical laboratories have validated laboratory developed tests (LDTs) for automated.
German researchers identify potential drug for Covid-19 pharmaceutical-technology
March 09, 2020
Scientists at the German Primate Center – Leibniz Institute for Primate Research have found that an existing drug may help treat Covid-19.
Preventing spread of SARS coronavirus-2 in humans worldpharmanews
March 06, 2020
Several coronaviruses circulate worldwide and constantly infect humans, which normally caused only mild respiratory disease.
Takeda initiates development of a plasma-derived therapy for COVID-19 expresspharma
March 05, 2020
Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed to treat infected, high-risk individuals with COVID-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page